Daiichi Sankyo, a global pharmaceutical company based in Japan, has announced its TaNeDS (Take a New challenge for Drug diScovery) collaborative drug discovery project for 2015. The company will select research partners for the project from researchers based in Japan. TaNeDS was launched in 2011 and has since received numerous research theme proposals from across Japan, with various projects currently ongoing.
Daiichi Sankyo will continue the program in 2015, seeking further drug discovery research possibilities by casting a wide net to find research themes and technologies that will result in the discovery of new drugs. Furthermore, continuing on from 2013 and 2014, Daiichi Sankyo’s wholly owned subsidiary Daiichi Sankyo RD Novare is again joining TaNeDS to promote the development of technology platforms for the next generation.
The TaNeDS project will accept entries in exploratory research, collaborative research, early-stage drug discovery and concepts for inventions. Themes covering all stages, from the initial phase of research to practical use, will be accepted. In order to attract a variety of entries, both individual researchers and groups are welcomed.
To efficiently realize practical uses from research results, a number of outcomes are foreseen, including further investigations into discovered results, collaborative research on drug creation and utilization of OiDE projects aimed at fostering intellectual property or technologies from a business viewpoint.
Desired research themes by Daiichi Sankyo:
Daiichi Sankyo will determine if feasibility studies with Daiichi Sankyo researchers (preliminary collaborative research or collaborative research) should be conducted based on proposed themes. Accepted themes will be selected for continuation based on results after the research period comes to a close.